Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | The potential of caplacizumab in the treatment of aTTP

Eleni Gavriilaki • 11 Dec 2023
ASH 2023
Immune Thrombocytopenia Non-Malignant Antibodies Caplacizumab Rituximab

Eleni Gavriilaki, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, speaks on the use of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). In a real-world multicenter study, patients treated with caplacizumab had more favorable outcomes compared to historic controls. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research Funding: Pfizer and Jazz Pharmaceuticals
Honoraria: Alexion, AstraZeneca, Omeros, Sanofi, Sobi

More from Eleni Gavriilaki

0:58
Agents under investigation for the treatment of TA-TMA
Eleni Gavriilaki • 16 Feb 2024
1:03
Cognitive impairment in patients receiving CAR T-cell therapy
Eleni Gavriilaki • 16 Feb 2024
0:52
Long-term complications in patients with hematological malignancies post-SCT
Eleni Gavriilaki • 11 Dec 2023
1:51
Targeting complement to treat PNH and other hematologic diseases
Eleni Gavriilaki • 11 Dec 2023

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals